Published in
American Society of Clinical Oncology, Journal of Clinical Oncology, 15_suppl(36), p. 9503-9503
DOI: 10.1200/jco.2018.36.15_suppl.9503
Links
Tools
4-year survival and outcomes after cessation of pembrolizumab (pembro) after 2-years in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in KEYNOTE-006.
Journal article published in 2018 by
Georgina V. Long,
Jacob Schachter,
Antoni Ribas,
Ana M. Arance,
Jean-Jacques Grob,
Laurent Mortier,
Adil Daud,
James M. G. Larkin,
Paul Lorigan,
Matteo S. Carlino 
,
Bart Neyns,
Catriona M. McNeil,
Christian U. Blank,
Michal Lotem,
Teresa M. Petrella
and other authors.
,
Bart Neyns,
Catriona M. McNeil,
Christian U. Blank,
Michal Lotem,
Teresa M. Petrella
and other authors.
This paper is made freely available by the publisher.
Full text: Download
Preprint: archiving forbidden
Published version:
archiving forbidden
Data provided by 